BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9576195)

  • 21. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.
    Orleans-Lindsay JK; Deru A; Craig JI; Prentice HG; Lowdell MW
    Clin Exp Immunol; 2003 Sep; 133(3):467-75. PubMed ID: 12930376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
    Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH
    Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
    Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
    Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
    Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
    Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy.
    Fischbacher D; Merle M; Liepert A; Grabrucker C; Kroell T; Kremser A; Dreyßig J; Freudenreich M; Schuster F; Borkhardt A; Kraemer D; Koehne CH; Kolb HJ; Schmid C; Schmetzer HM
    Cell Commun Adhes; 2015; 22(2-6):49-65. PubMed ID: 27602789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent approaches to induction of cytotoxic lymphocytes against leukemia.
    Lotzová E
    Leukemia; 1993 Aug; 7 Suppl 2():S69-74. PubMed ID: 8361237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of cytokines and autologous lymphokine-activated killer cells on leukemic bone marrow cells and colonies in AML.
    Braun SW; Gerhartz HH; Schmetzer HM
    Acta Haematol; 2001; 105(4):209-21. PubMed ID: 11528095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
    Wong EK; Eaves C; Klingemann HG
    Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-3 priming in acute myeloid leukaemia patients.
    Tafuri A; de Felice L; Goodacre A; Fenu S; Petrucci MT; Valentini T; Alimena G; Petti MC; Meloni G; Mandelli F
    Br J Haematol; 1995 Sep; 91(1):234-44. PubMed ID: 7577641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conjugate formation by leukemic blasts from acute myeloid leukemia with cytotoxic lymphocytes.
    Palucka AK; Porwit A; Reizenstein P
    Leuk Lymphoma; 1993 Nov; 11(5-6):427-33. PubMed ID: 7907248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.
    Gangal SG; Damle NK; Khare AG; Advani SH
    Br J Cancer; 1979 Sep; 40(3):391-6. PubMed ID: 292450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Core-binding factor-beta positive acute myeloid leukaemia cells induce T-cell responses.
    Banat GA; Ihlow K; Usluoglu N; Hoppmann S; Hoeck M; Pralle H
    Br J Haematol; 2003 Dec; 123(5):819-29. PubMed ID: 14632772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1.
    Hirst WJ; Buggins A; Darling D; Gäken J; Farzaneh F; Mufti GJ
    Gene Ther; 1997 Jul; 4(7):691-9. PubMed ID: 9282170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.
    Orleans-Lindsay JK; Barber LD; Prentice HG; Lowdell MW
    Clin Exp Immunol; 2001 Dec; 126(3):403-11. PubMed ID: 11737054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.